In this report, the global consumption of varicella attenuated live vaccine products rises up from 34.99million doses in 2012 to 39.81 million doses in 2016, with an average annual growth rate of 3.44 %. At the same time, the revenue of world varicella attenuated live vaccine market has a leap from 1154.37 million dollars to 1515.52 million dollars. The reason causes this increase is the growing demand for the varicella attenuated live vaccine products, which is the outcome of the downstream industries are in a good situation.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The classification of consumption of varicella attenuated live vaccine includes Monovalent Vaccine and Combination Vaccine, and the revenue proportion of Monovalent Vaccine in 2016 was about 94.4%.
The downstream industries of varicella attenuated live vaccine products are kids and adults. In the recent years, with the recovery of global economic, the development of emerging countries and the rising health concern, the consumption increase of varicella attenuated live vaccine will be obvious. In the foreseeable future, the varicella attenuated live vaccine products will show an optimistic upward trend.
As for the global varicella attenuated live vaccine industry, the industry structure is relatively concentrated. 60.07% of market share in sales was grasped by Merck and GSK. The United States giant Merck, which had 48.70% market share in 2016, was the leader in the varicella attenuated live vaccine industry. The manufacturers following Merck are GSK and BCHT, which respectively had 11.3% and 10.8% market share globally. The BCHT was the leader of China varicella attenuated live vaccine industry. It sold a total of 76.26 million dollars in the year of 2016.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Varicella Attenuated Live Vaccine in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Varicella Attenuated Live Vaccine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Company Name
Website
Company Type
Company Profile
Employees or Revenue
Products and Services
Established Date
Market Position or History
Contact Information
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Monovalent Vaccine
Combination Vaccine
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Varicella Attenuated Live Vaccine for each application, including
Kids Injection
Adults Injection
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Varicella Attenuated Live Vaccine Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Varicella Attenuated Live Vaccine Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Monovalent Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Combination Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Varicella Attenuated Live Vaccine Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Varicella Attenuated Live Vaccine Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Varicella Attenuated Live Vaccine Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Varicella Attenuated Live Vaccine Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Varicella Attenuated Live Vaccine Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Varicella Attenuated Live Vaccine Market Assessment by Type
8.1 Asia Pacific Varicella Attenuated Live Vaccine Market Assessment by Application (Consumption and Market Share)
8.2 North America Varicella Attenuated Live Vaccine Market Assessment by Application (Consumption and Market Share)
8.3 Europe Varicella Attenuated Live Vaccine Market Assessment by Application (Consumption and Market Share)
8.4 South America Varicella Attenuated Live Vaccine Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Varicella Attenuated Live Vaccine Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Company Name
9.1.1 Company Name Profiles
9.1.2 Company Name Product Portfolio
9.1.3 Company Name Varicella Attenuated Live Vaccine Business Performance
9.1.4 Company Name Varicella Attenuated Live Vaccine Business Development and Market Status
9.2 Website
9.2.1 Website Profiles
9.2.2 Website Product Portfolio
9.2.3 Website Varicella Attenuated Live Vaccine Business Performance
9.2.4 Website Varicella Attenuated Live Vaccine Business Development and Market Status
9.3 Company Type
9.3.1 Company Type Profiles
9.3.2 Company Type Product Portfolio
9.3.3 Company Type Varicella Attenuated Live Vaccine Business Performance
9.3.4 Company Type Varicella Attenuated Live Vaccine Business Development and Market Status
9.4 Company Profile
9.4.1 Company Profile Profiles
9.4.2 Company Profile Product Portfolio
9.4.3 Company Profile Varicella Attenuated Live Vaccine Business Performance
9.4.4 Company Profile Varicella Attenuated Live Vaccine Business Development and Market Status
9.5 Employees or Revenue
9.5.1 Employees or Revenue Profiles
9.5.2 Employees or Revenue Product Portfolio
9.5.3 Employees or Revenue Varicella Attenuated Live Vaccine Business Performance
9.5.4 Employees or Revenue Varicella Attenuated Live Vaccine Business Development and Market Status
9.6 Products and Services
9.6.1 Products and Services Profiles
9.6.2 Products and Services Product Portfolio
9.6.3 Products and Services Varicella Attenuated Live Vaccine Business Performance
9.6.4 Products and Services Varicella Attenuated Live Vaccine Business Development and Market Status
9.7 Established Date
9.7.1 Established Date Profiles
9.7.2 Established Date Product Portfolio
9.7.3 Established Date Varicella Attenuated Live Vaccine Business Performance
9.7.4 Established Date Varicella Attenuated Live Vaccine Business Development and Market Status
9.8 Market Position or History
9.8.1 Market Position or History Profiles
9.8.2 Market Position or History Product Portfolio
9.8.3 Market Position or History Varicella Attenuated Live Vaccine Business Performance
9.8.4 Market Position or History Varicella Attenuated Live Vaccine Business Development and Market Status
9.9 Contact Information
9.9.1 Contact Information Profiles
9.9.2 Contact Information Product Portfolio
9.9.3 Contact Information Varicella Attenuated Live Vaccine Business Performance
9.9.4 Contact Information Varicella Attenuated Live Vaccine Business Development and Market Status
10 World Varicella Attenuated Live Vaccine Market Assessment by Players
10.1 Global Varicella Attenuated Live Vaccine Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Varicella Attenuated Live Vaccine Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Varicella Attenuated Live Vaccine Price (USD/Unit) of Players 2014-2020
10.4 Global Varicella Attenuated Live Vaccine Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Varicella Attenuated Live Vaccine Sales Assessment of Players 2014-2020
11.1.2 North America Varicella Attenuated Live Vaccine Revenue Assessment of Players 2014-2020
11.1.3 North America Varicella Attenuated Live Vaccine Price Assessment of Players 2014-2020
11.1.4 North America Varicella Attenuated Live Vaccine Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Varicella Attenuated Live Vaccine Sales Assessment of Players 2014-2020
11.2.2 Europe Varicella Attenuated Live Vaccine Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Varicella Attenuated Live Vaccine Price Assessment of Players 2014-2020
11.2.4 Europe Varicella Attenuated Live Vaccine Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Varicella Attenuated Live Vaccine Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Varicella Attenuated Live Vaccine Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Varicella Attenuated Live Vaccine Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Varicella Attenuated Live Vaccine Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Varicella Attenuated Live Vaccine Sales Assessment of Players 2014-2020
11.4.2 South America Varicella Attenuated Live Vaccine Revenue Assessment of Players 2014-2020
11.4.3 South America Varicella Attenuated Live Vaccine Price Assessment of Players 2014-2020
11.4.4 South America Varicella Attenuated Live Vaccine Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Varicella Attenuated Live Vaccine Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Varicella Attenuated Live Vaccine Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Varicella Attenuated Live Vaccine Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Varicella Attenuated Live Vaccine Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Varicella Attenuated Live Vaccine Sales by Countries/Regions 2014-2020
12.2.2 North America Varicella Attenuated Live Vaccine Revenue by Countries/Regions 2014-2020
12.2.3 North America Varicella Attenuated Live Vaccine Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Varicella Attenuated Live Vaccine Sales by Countries/Regions 2014-2020
12.3.2 Europe Varicella Attenuated Live Vaccine Revenue by Countries/Regions 2014-2020
12.3.3 Europe Varicella Attenuated Live Vaccine Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Varicella Attenuated Live Vaccine Sales by Countries/Regions 2014-2020
12.4.2 South America Varicella Attenuated Live Vaccine Revenue by Countries/Regions 2014-2020
12.4.3 South America Varicella Attenuated Live Vaccine Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Varicella Attenuated Live Vaccine Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Varicella Attenuated Live Vaccine Sales & Revenue Forecast 2021-2026
14.1 World Varicella Attenuated Live Vaccine Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Varicella Attenuated Live VaccineSales and Market Share by Regions
14.1.2 World Varicella Attenuated Live VaccineRevenue and Market Share by Regions
15 Asia Varicella Attenuated Live Vaccine Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Monovalent Vaccine
15.1.2 Combination Vaccine
15.2 Consumption Forecast by Application, 2021-2026
16 North America Varicella Attenuated Live Vaccine Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Monovalent Vaccine
16.1.2 Combination Vaccine
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Varicella Attenuated Live Vaccine Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Monovalent Vaccine
17.1.2 Combination Vaccine
17.2 Consumption Forecast by Application, 2021-2026
18 South America Varicella Attenuated Live Vaccine Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Monovalent Vaccine
18.1.2 Combination Vaccine
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Varicella Attenuated Live Vaccine Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Monovalent Vaccine
19.1.2 Combination Vaccine
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Varicella Attenuated Live Vaccine Price (USD/Unit) Trend 2021-2026
20.2 Global Varicella Attenuated Live Vaccine Gross Profit Trend 2021-2026
21 Conclusion
| Price : US$ 2450 | Date : Apr 2024 |
| Category : Manufacturing and Construction | Pages : 260 |
| Price : US$ 3500 | Date : Mar 2024 |
| Category : Consumer Goods and Retail | Pages : 140 |
| Price : US$ 3500 | Date : Mar 2024 |
| Category : Manufacturing and Construction | Pages : 125 |
| Price : US$ 3500 | Date : Feb 2024 |
| Category : Services | Pages : 120 |
| Price : US$ 3500 | Date : Feb 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 142 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
